EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of the AHR Inhibitor CH223191 as an Adjunct Treatment for Mammarenavirus Infections

Miguel Angel Pelaez, Jonna B Westover iD, Dionna Scharton, Cybele Carina García iD, Brian B Gowen iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27021071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Miguel Angel Pelaez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Estrategias Antivirales, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA…. Hauptthemen laut MEDLINE: Antiviral Agents, Receptors, Aryl Hydrocarbon, Arenaviridae Infections, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Investigaciones Científicas y Técnicas, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Universidad de Buenos Aires.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The family Arenaviridae encompasses zoonotic, rodent-borne pathogens (e.g., Lassa, Machupo, and Junín viruses) that cause severe viral hemorrhagic fevers with high case fatality rates. The current therapeutic landscape is severely limited, underscoring the urgent need for novel antiviral strategies. A promising approach involves combining directly acting antivirals with host-targeted antivirals. A compelling host-targeted antiviral target is the aryl hydrocarbon receptor (AHR). This ubiquitous ligand-activated transcription factor is a recognized pro-viral host factor across multiple viral families. Building on prior work with Junín and Tacaribe viruses, we investigated whether the AHR inhibitor CH223191 could enhance the virus-directed antiviral activity of favipiravir against these viruses. First, we evaluated the toxicity and antiviral potential of CH223191 against a lethal Junín virus infection in male and female hTfR1 mice. After demonstrating substantial protection, we conducted preliminary assays to study the antiviral effects of combining CH223191 and favipiravir on Tacaribe virus (TCRV) infections in the Vero cell culture model. We observed synergistic interaction with all four models (ZIP, Loewe, Bliss, and HSA). We next determined the sub-optimal dose of favipiravir and conducted an antiviral combination study in the AG129 mouse model infected with TCRV. The combination effectively protected mice from a lethal TCRV infection and showed cooperative effects, reducing weight loss and viral loads. Overall, these results show that the AHR is a promising pharmacological target for the development of novel antivirals. Furthermore, we discovered a cooperative interaction between the activities of favipiravir and CH223191.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsReceptors, Aryl HydrocarbonArenaviridae InfectionsPyrazolesAnimalsFemalePyrazinesMiceChlorocebus aethiopsVero CellsAmidesMaleJunin virusHumansDrug SynergismCytosineOrganophosphonates

Stichwörter der Autor:innen

Junín virusTacaribe virusantiviralsaryl hydrocarbon receptorfavipiravirsynergy analysisviral hemorrhagic fevers

Substanzen

Antiviral AgentsReceptors, Aryl HydrocarbonPyrazinesfavipiravirAmidesPyrazolesbrincidofovirCytosineOrganophosphonates

Autor:innen und Institutionen

  • Laboratorio de Estrategias Antivirales, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Buenos Aires 1428, Argentina.
  • Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.
  • Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), UBA-CONICET, Buenos Aires 1428, Argentina.

ORCID-Profile: Jonna B Westover, Cybele Carina García, Brian B Gowen

Förderung

  • Consejo Nacional de Investigaciones Científicas y Técnicas
  • Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
  • Universidad de Buenos Aires
  • NIAID NIH HHS
  • Agencia Nacional de Promoción Científica y Tecnológica
  • Consejo Nacional de Investigaciones Científicas y Tecnológicas
  • National Institute of Allergy and Infectious Diseases (Preclinical Services), National Institutes of Health

Zitieren

APA

Pelaez, M. A., Westover, J. B., Scharton, D., García, C. C., & Gowen, B. B. (2026). Effect of the AHR Inhibitor CH223191 as an Adjunct Treatment for Mammarenavirus Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27021071

Vancouver

Pelaez MA, Westover JB, Scharton D, García CC, Gowen BB. Effect of the AHR Inhibitor CH223191 as an Adjunct Treatment for Mammarenavirus Infections. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27021071

BibTeX
@article{Pelaez2026,
  author = {Pelaez, Miguel Angel and Westover, Jonna B and Scharton, Dionna and García, Cybele Carina and Gowen, Brian B},
  title = {Effect of the AHR Inhibitor CH223191 as an Adjunct Treatment for Mammarenavirus Infections},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27021071}
}
Kostenlos starten →